Last reviewed · How we verify
aricept Tab
Aricept (donepezil) is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.
Aricept (donepezil) is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease. Used for Alzheimer's disease, Vascular dementia.
At a glance
| Generic name | aricept Tab |
|---|---|
| Sponsor | Icure Pharmaceutical Inc. |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the enzyme acetylcholinesterase, donepezil increases the levels of acetylcholine in the brain, which is a neurotransmitter that plays a key role in memory and learning. This can help to slow down the progression of Alzheimer's disease symptoms and improve cognitive function in patients with mild to moderate dementia.
Approved indications
- Alzheimer's disease
- Vascular dementia
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Fatigue
- Headache
Key clinical trials
- Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (PHASE2)
- Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease (NA)
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Effect of Acetylcholinesterase Inhibitors on Bone Metabolism (PHASE2)
- Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type (PHASE2, PHASE3)
- Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) (PHASE1)
- Rivastigmine Mini-Tablet for Alzheimer's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aricept Tab CI brief — competitive landscape report
- aricept Tab updates RSS · CI watch RSS
- Icure Pharmaceutical Inc. portfolio CI